Addition of a selective inhibitor of JNK activation together with our dual treatment in turn increased viability of myeloma cells, implicating that activation of JNK in our treatment regimen is a pivotal mechanism for the targeting of MM cells with the combination of proteasome inhibitors and inhibitors of autophagy. Here, MAPK8 is linked to Miyoshi myopathy.